Literature DB >> 8105680

Sulfasalazine-associated encephalopathy in a patient with Crohn's disease.

R Schoonjans1, A Mast, G Van den Abeele, D Dewilde, E Achten, V Van Maele, W Pauwels.   

Abstract

We report a case of acute encephalopathy in a patient with Crohn's disease who had taken sulfasalazine for 1 month. The development of toxic hepatitis and dermatitis prompted interruption of the drug. Four days later, neurologic symptoms became evident. These included acute monoparesis of the left arm, the development of stupor and coma, with endorotation of both arms, and a left Babinski sign. CT and MR imaging revealed multiple lesions in the white and gray brain matter, suggesting diffuse cerebral microangiitis. All cerebrospinal fluid examinations were negative. Methylprednisolone was given intravenously. Complete clinical normalization followed. Neurotoxicity secondary to sulfasalazine has seldom been reported in the literature. We found certain similarities with two previous case reports suggesting a hypersensitivity reaction to sulfasalazine or one of its metabolites. For ethical reasons, no rechallenge was performed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105680

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  2 in total

1.  Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.

Authors:  Pierre A Robe; Didier H Martin; Minh T Nguyen-Khac; Maria Artesi; Manuel Deprez; Adelin Albert; Sophie Vanbelle; Stephane Califice; Markus Bredel; Vincent Bours
Journal:  BMC Cancer       Date:  2009-10-19       Impact factor: 4.430

2.  An unusual cause for collapse in a patient with arthritis.

Authors:  K J Heath; M J Sampson; S A Ridley
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.